This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Good afternoon, and welcome to Etan Pharmaceuticals' third quarter 2022 financial results conference call. At this time, all participants are on a listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn the call over to David Kempa, Senior Vice President of Business Development and Investor Relations at Etan Pharmaceuticals. Please proceed.
spk04: Thank you, operator. Good afternoon, everyone, and welcome to Eaton's third quarter 2022 conference call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, eatonpharma.com. Joining me on our call today, we have Sean Brinjelson, our CEO, and James Gruber, our CFO. In addition to taking live questions on today's call, We will also be answering questions that are emailed to us. Investors can send their questions to investorrelations at etanpharma.com. Before we begin, I would like to remind everyone that remarks made during the call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC. Now, I will turn the call over to our CEO, Sean Brynjolfsson.
spk06: Thanks, David. Good afternoon, everyone, and thank you for joining us to discuss Eaton's third quarter results. With another strong quarter for the company with total revenue up 315% compared to the prior year period. Revenue from product sales and royalties continue to increase sequentially with a 37% jump from Q2, representing the seventh straight quarter of growth driven primarily by alkindi-sprinkle and curglimic acid. Feedback from parents and physicians continues to be overwhelmingly positive about alkindi-sprinkle, the first and only hydrocortisone treatment designed specifically to provide accurate dosing for newborns and children with adrenal insufficiency. The product addresses the huge unmet need for a low dose option. Third quarter sales of Alkindi were up 19% over the second quarter, and we continue to see steady growth in prescriptions each month, coming from both new prescribers as well as existing prescribers who have added new patients after seeing positive results from their initial patients. We're excited about the $100 million market opportunity and believe the product has a long runway to grow for many years to come. The second product driving our Q3 revenue growth was carglymic acid. We continue to see a strong reception for the product with revenue increasing 40% over the prior quarter. Carglymic acid is a lower cost alternative to Carboglu, and with the cost of Carboglu exceeding $1 million annually for some patients, prescribers have been very excited that we brought a lower cost alternative to market, while still offering the patient support services that they have grown accustomed to for rare disease products. The prescribers and patients also appreciate the fact that our tablets do not require refrigeration, which provides an additional convenience benefit to patients. Hergulamic acid tablets have now been commercially available for three full quarters, and we believe we remain on track to capture approximately 25 to 35% market share of the estimated 50 million plus market. We were thrilled to add a third commercial product to our rare disease portfolio during the quarter. with the recently announced acquisition of betaine anhydrase for oral solution for the treatment of homocystinuria. Betaine is a powerful tuck-in acquisition for us. It is an FDA-approved rare disease product, an ideal strategic fit for existing commercial infrastructure, and is expected to be accretive to our 2023 earnings. The product has the same metabolic geneticist-prescriber base that we already have relationships with, so we believe we are uniquely positioned to commercialize this product. The addition of betaine to our portfolio will help strengthen our relationship with these doctors and allow us to increase our frequency of communication with them, which may also benefit our caglomic acid sales. We expect the product to contribute multiple millions of dollars of revenue annually with very little incremental cost to us. We've already heard from a number of prescribers that are eager to begin prescribing our product, and we are working with our supply chain partners to make the product available as soon as possible. Also during the quarter, we were pleased to see the FDA approval for zonicide, the first and only FDA-approved oral liquid formulation of zonisamide, an anticonvulsant used to treat patients with epilepsy. This application was filed with the FDA by Eaton and then became part of our multi-product neurology oral solution agreement with Azurity Pharmaceuticals. This was the seventh FDA approval that our team has been a part of, and I am very proud of all the hard work put into the program over the last few years. Azure AD will be responsible for commercializing the product, and we will receive a $5 million payment upon launch of the product. We are entitled to receive additional milestone payments as well as an ongoing royalty and commercial sales. I am pleased to report that the product was launched in October, which triggered the second milestone payment of $5 million, which will be recorded as revenue in our fourth quarter results. Since this launch occurred after the third quarter ended, this $5 million benefit was not reflected in the cash balance that we've reported today. Now I'd like to turn over to the late-stage pipeline candidates, which we are also very excited about. On dehydrated alcohol, Eaton is close to finalizing the FDA response. Now that we've thoroughly addressed each of the FDA's concerns and requests, our goal is to have it resubmitted later this month, and we feel confident about the likelihood of approval. We expect that our submission will be assigned a six-month review cycle, which would allow for approval and launch of the product in the middle of next year. This product is a very compelling market opportunity. Based on the latest IQVIA data, the annualized market opportunity is approximately 80 million. We expect to be one of only two players in this market and are protected by orphan drug exclusivity, so our product should take a significant share of the market. We also made strong progress this quarter on our ET400 product candidate. This is a pediatric endocrinology product that has been requested extensively by physicians and parents that we've engaged with while promoting LKD sprinkle. We have successfully manufactured our registration batches, which should allow us to file the NDA for the product before the end of 2023. We expect to be able to share additional details about this product shortly. The other product that is consistently requested by pediatric endocrinology community is our Xenio Hydrocortisone Autoinjector, which is under development as a rescue treatment for adrenal crisis. This innovative product would solve a major hurdle to current treatment as many caregivers and patients are intimidated by the dilution, mixing, and administration complexities associated with the Solu-Cortif Lyophilized Kit that is the standard of care today. The complexity of the standard treatment often limits a child's ability to participate in sports or other extracurricular activities where a parent or trained caregiver is not available to administer treatment. Due to a slight delay at the European manufacturer, we now think that products NDA could be filed in early 2024 rather than the end of 2023, but we remain very optimistic about the opportunity to bring this product to patients. With this attractive late stage pipeline, commercial products that are still in the early innings of their launch, we are extremely excited about the outlook for 2023 and beyond. Alkindi sprinkle and cargumic acid alone are poised to deliver major growth for the company in 2023. We are now adding in the launch of betaine as well to that and the expected launch of dehydrated alcohol in the middle of next year. These products should allow us to deliver very attractive revenue growth and more importantly, help us reach profitability in 2023. For more information about our financial position, I'll now turn the call over to James. James? Thank you, Sean.
spk03: Our third quarter revenue was $3.2 million compared to $0.8 million in the third quarter of 2021, or a 315% increase. In both periods, revenue was comprised entirely of product sales and royalties. Gross profit for the quarter was $2.0 million compared with $0.1 million in the prior year period. R&D expenses for the quarter were $0.7 million compared with $2.7 million in the prior year period. The decrease was primarily due to a $1.1 million fee related to the biorphine and resopress vial projects in the prior year period and decreased development costs for new product candidates as we approached commercialization. General and administrative expenses for the quarter were $4.2 million compared with $3.3 million in the prior year period. The increase in G&A expenses was mainly due to incremental marketing and compensation to support our product sales growth, partially offset by decreased legal and consulting expenses. Total company net loss was $3.0 million for the third quarter, compared to a net loss of $6.1 million in the prior year period. Eaton finished the third quarter with $13.4 million of cash on hand. This does not include the $5 million milestone payment for the zone estate launch we expect to receive in the fourth quarter. Our operating cash flow during the quarter was negative $1.7 million. As Sean mentioned, we are confident that our cash on hand, licensing payments, and royalty income will give us the flexibility to support our ongoing commercial growth and continue investing in new product opportunities. This concludes our remarks on third quarter results, and with that, we'll turn it over to the operator for Q&A.
spk01: Thank you. Ladies and gentlemen, to ask a question on the phone line, you will need to press star 1 1 on your telephone keypad.
spk02: One moment, please, to see if there's any questions in the queue. I see no phone questions at this time.
spk05: Thank you, operator. We can take the emailed questions that we've received. First question, I guess this one's for James. Your G&A expense declined significantly from $5.3 million in Q2 to $4.2 million this quarter. What type of run rate are you expecting going forward?
spk03: The decrease in G&A from Q2 to Q3 was driven primarily by a handful of one-time items that occurred in Q2, some severance, share-based comp, and legal fees So, Q3 was a better representation. We expect approximately 4.5 million in GNA going forward.
spk05: Next question for Sean. Can you provide an update on the dehydrated alcohol resubmission?
spk06: Sure. The resubmission is largely complete. We're expecting to have that ideally submitted before the end of this month. And if not, it would be really early December due to the holidays. So I expect that either to have a Most likely a six-month review process, so that would put us in the second quarter. In terms of approval, there is potential. Obviously, it could be a three-month review. We'll certainly let folks know once we get guidance from the agency. And our last question is, when do you expect to launch Betaine? We're excited to launch that product, obviously, as quickly as possible. We're working with our supply chain partners to make it available. There's no showstoppers. It's just a matter of going through the operational process of producing the batches and then having them tested and released. I think early next year is a good timeframe I'm comfortable with, and it's a great opportunity. It fits well with our coagulant acid sales team, and yeah, the doctors so far are looking forward to us bringing that to market.
spk05: That's the end of our emailed questions. Thank you, everyone, for joining us today.
spk02: Ladies and gentlemen, that does end our conference for today. Thank you for your participation. You may now disconnect.
Disclaimer